Trump Fast-Tracks Psychedelic Drug Research

0:00It's April 18th. Welcome in. This is Canada News Today, where local news meets AI. I'm Corey with the story. President Trump just signed an executive order to fast track reviews on psychedelic drugs like IBOLGain, a substance stuck in the most restricted federal ban category. It's got big promise for treating tough issues like post-traumatic stress disorder and opioid addiction, especially among combat veterans. Trump says this could dramatically speed up research and help folks reclaim their lives. Earlier this week, Health Secretary Robert F. Kennedy Jr. and other officials pledged easier access, pulling rare bipartisan backing. Next week, the Food and Drug Administration plans to issue national priority vouchers for three psychedelics, the first time ever for this fast track, approval if they match key health goals. They're also clearing paths for the first human trials of IBOLGain right here in the United States. Veterans and advocates are buzzing, with groups saying IBOLGain from a West African

1:01shrub has changed lives, like one vet telling Trump it saved his, but it's risky, linked to hard issues and over 30 deaths and studies. Clinics abroad monitor hearts closely and keep emergency gear ready. A small Stanford study on 30 veterans treated in Mexico showed gains in traumatic brain injury symptoms, PTSD, depression, and anxiety using. IBOLGain mixed with magnesium to cut risks. No placebo group though, so more rigorous work is needed. This move acknowledges psychedelics federally, easing stigma around schedule one, drugs and potentially sparking state-funded research. If it pans out, we could see real breakthroughs hitting closer to home soon.